Human factors study validates Bmab 1200 autoinjector for ustekinumab delivery
The Bmab 1200 autoinjector showed high usability and safety in a human factors validation study with 100% successful unaided injections.
Asset / Drug
Drug and asset intelligence for ustekinumab with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.